Fig. 4From: Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysisForest plots of common adverse events and cardiotoxicity events in single-arm studies: combination of pertuzumab with HER2 inhibitors for patients with HER2+ breast cancer. HER2 = human epidermal growth factor receptor 2Back to article page